245 related articles for article (PubMed ID: 34943916)
21. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor status predicts development of brain metastases in ovarian cancers.
Mittica G; Senetta R; Scotto G; Aglietta M; Maggiorotto F; Ghisoni E; Genta S; Boldorini R; Manini C; Morra I; Buosi R; Sapino A; Cassoni P; Valabrega G
Oncotarget; 2017 Jun; 8(25):41143-41153. PubMed ID: 28467804
[TBL] [Abstract][Full Text] [Related]
23. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
24. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
[TBL] [Abstract][Full Text] [Related]
25. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.
Yan Z; Tian X; Wang R; Cheng X; Mi J; Xiong L; Wang Y; Deng J; Jia M
Int J Gynecol Cancer; 2017 Sep; 27(7):1343-1349. PubMed ID: 30814239
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
27. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.
Pectasides D; Aravantinos G; Fountzilas G; Kalofonos C; Efstathiou E; Karina M; Pavlidis N; Farmakis D; Economopoulos T; Dimopoulos MA
Anticancer Res; 2005; 25(5):3553-8. PubMed ID: 16101179
[TBL] [Abstract][Full Text] [Related]
28. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
Han GH; Hwang I; Cho H; Ylaya K; Choi JA; Kwon H; Chung JY; Hewitt SM; Kim JH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071938
[TBL] [Abstract][Full Text] [Related]
30. Role of protein tyrosine phosphatase receptor type M in epithelial ovarian cancer progression.
Li X; Ding W; Rao Y; Qu P
J Ovarian Res; 2023 Jul; 16(1):131. PubMed ID: 37403117
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
32. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
Jernigan AM; Mahdi H; Rose PG
Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
[TBL] [Abstract][Full Text] [Related]
33. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
34. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
[TBL] [Abstract][Full Text] [Related]
35. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
[TBL] [Abstract][Full Text] [Related]
36. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
37. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
[TBL] [Abstract][Full Text] [Related]
38. A Multiplex Biomarker Assay Improves the Prediction of Survival in Epithelial Ovarian Cancer.
Dobilas A; Åkesson A; Leandersson P; Borgfeldt C
Cancer Genomics Proteomics; 2023; 20(3):273-280. PubMed ID: 37093685
[TBL] [Abstract][Full Text] [Related]
39. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
40. Central nervous system metastasis from epithelial ovarian cancer- predictors of outcome.
Jayraj AS; Kumar S; Bhatla N; Malik PS; Mathur S; Rangarajan K; Vanamail P; Thulkar S; Kumar L
Curr Probl Cancer; 2023 Feb; 47(1):100918. PubMed ID: 36502584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]